ESTRO 2024 - Abstract Book

S4898

Physics - Quality assurance and auditing

ESTRO 2024

Conclusion:

The results indicate that achieving clinically acceptable agreement with the predicted dose distributions is feasible across all treatment delivery systems. This intercomparison provided an opportunity for radiotherapy departments to assess the quality of their SRS treatment planning and delivery, benchmark their performance against other institutions, and identify areas where improvement is needed.

Keywords: SRS, Quality Assurance, Dosimetric Intercomparison

References:

1. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, Yamanaka K, Sato Y, Jokura H, Yomo S, Nagano O. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. The Lancet Oncology. 2014 Apr 1;15(4):387-95. 2. Niranjan A, Monaco E, Flickinger J, Lunsford LD. Guidelines for multiple brain metastases radiosurgery. Leksell Radiosurgery. 2019; 34:100-9. 3. Hughes RT, Masters AH, McTyre ER, Farris MK, Chung C, Page BR, Kleinberg LR, Hepel J, Contessa JN, Chiang V, Ruiz J. Initial SRS for patients with 5 to 15 brain metastases: results of a multi-institutional experience. International Journal of Radiation Oncology* Biology* Physics. 2019 Aug 1;104(5):1091-8. 4. Vergalasova I, Liu H, Alonso-Basanta M, Dong L, Li J, Nie KE, Shi W, Teo BK, Yu Y, Yue NJ, Zou W. Multi institutional dosimetric evaluation of modern-day stereotactic radiosurgery (SRS) treatment options for multiple brain metastases. Frontiers in Oncology. 2019 Jun 7; 9:483.